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SJOGREN'S SYNDROME:
Recognizing and Treating
an Autoimmune Disease
Susan DeNisco, APRN, MS, FNP
Linda Ferro, MSN, APRN, FNP

Sjogren's syndrome, one of the most common autoimmune diseases, is characterized hy cell-mediated lymphocytic infiltration of the exocrine glands, particularly
the salivary and lacrimal glands.' It receives little
attention in the literature, and frequently goes unrecognized until progressive changes are apparent. This article aids nurse practitioners in diagnosing the disorder
in its earliest stages and in initiating proper treatment.

S

jogren's syndrome was first identified in 1933 by a
Swedish ophthalmologist named Henrik Sjögren, who
reported the association between dryness of the mouth
(xerostomia), dryness of the eyes (xerophthalmia), and chronic
deforming arthritis. It can develop as a primary disorder (classic clinical features include parotid gland enlargement, xerostomia, and xerophthalmia), or it may be secondary to an
extraglandular connective tissue disease, typically rheumatoid
arthritis (RA), systemic lupus erythematosus (SLF), polymyositis, systemic sclerosis, or biliary cirrhosis.'' Primary Sjogren's is
sometimes referred to as keratoconjunctivitis sicca (KCS), the
sicca complex, or the sicca syndrome. In either its primary or
secondary form, Sjogren's syndrome may progress in severity
and lead to end-organ damage.

Incidence
Sjogren's syndrome affects 2 to 4 million persons in the United
States, predominantly middle-aged women in the perimenopausal or postmenopausal stage of life (it is 10 times more
common in females than in males). The mean age at diagnosis is
50 years.^ Sjogren's syndrome occurs in persons of all races, but
it is rarely seen in children. Thirty percent of patients with
autoimmune rheumatic disease suffer from secondary Sjogren's.'

Pathophysiology
The pathophysiologic process appears to be autoimmune in
nature. Antibodies produce sensitized lymphocytes, which
selectively seek, infiltrate, and destroy exocrine glandular tissue. This phenomenon is characterized clinically by depressed
production of tears and saliva.^ Over time, the attack on the
body's immune system may lead to inflammation of internal
organs, causing irreversible damage. The specific cause of
Sjogren's remains unknown, but it is likely that genetic, environmental, and infectious factors are involved.^ Retroviruses,
Fpstein-Barr virus (FBV), and, most recently, hepatitis C \arus
(HCV) have been implicated as causative pathogens.' Fvidence
also suggests that certain hormones, particularly estrogen, may
influence the autoimmune response in a manner simflar to that
noted in diabetes or thyroiditis."

Clinical Presentation
In clinical practice, two presentations of Sjogren's syndrome are
seen most frequently. One is the rapid development of severe
xerostomia and xerophthalmia, which is frequently accompanied by episodic parotid swelling in an otherwise healthy person (primary Sjogren's). Female patients are also likely to
experience vaginal dryness. The other presentation is the insidious and slowly progressive development of the sicca complex
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in patients with RA or another connective
tissue disorder (secondary Sjogren's).'"
Because the s)'mptoms of decreased salivary and lacrimal function are often subtle, the diagnosis is often delayed until
severe symptoms are present. Other early
manifestations of secondary Sjögrens
syndrome may include fatigue, arthralgias, Raynaud's phenomenon (intermittent bilateral ischemia of the fingers, toes,
and sometimes the ears and nose, with
severe pallor and often paresthesias and
pain, usually brought on by cold and
relieved by heat), loss of appetite, and
weight loss. It is not uncommon for 8 to
10 years to elapse between symptom
onset and the development of extraglandular complications.'

Diagnosis
As an autoimmune disease, Sjögren's
syndrome can pose a challenge to primary care practitioners in terms of diagnosis, particularly in the early stages.
An accurate diagnosis of Sjogren's is
obtained through a comprehensive history, a focused physical examination,
and selective diagnostic testing. Table 1
lists signs and symptoms that are characteristic of the syndrome. These clinical
features should be considered in tbe
review of symptoms when Sjögren's is
part of the differential diagnosis.^ Table
2 lists the San Diego diagnostic criteria
for Sjögrens syndrome.' These criteria
are stringent, requiring evidence for an
autoimmune process associated with
destruction of salivary and lacrimal
gland ttssues. At the other extreme, several groups (including the Copenhagen
and EEC Study group) have based their
diagnostic criteria for Sjögren's syndrome on clinical findings of dry eyes
and mouth, with no absolute requirement for gland biopsy or presence of
autoantibodies.' The EEC study group
believes that the San Diego criteria identify only the tip of the iceberg—namely,
those patients with full-blown disease—
and ignore those patients with milder
forms of Sjögren's syndrome.'
Differential Diagnosis—Sjögren's
syndrome is not the only disease process
that can cause lacrimal and salivary
gland dysfunction. A comprehensive differential diagnosis must be considered

TABLE 1

SIGNS AND SYMPTOMS OF SJÖGREN'S SYNDROME^

ORAL/SALIVARY MANIFESTATIONS
Dry moufh
Fissures and ulcers of fhe tongue,
buccal mucosa, and lips
Pefechial lesions on fhe hard palafe
Lichen planus-like appearance of
buccal mucosa
Cobblesfone appearance of fongue
Inflamed oral mucous membranes
Parofid gland hardening and/ar
enlargement
Dental caries
Adherence of food fo mucosal
surfaces
Dysphagia (especially dry foods)
Difficulty chewing
Reduced salivary flow rates
Changes in or loss of senses of taste
and odor
Frequency chronic candidiasis
infections
Inability to speak continuously
OCULAR MANIFESTATIONS
Foreign body sensation
Decreased tear production
Inability fo fear
Light intolerance
Filamenfs of mucus on corneal
surface
Inflammation, erythema
Eye fatigue
Corneal ulcérations
Increased blinking
Visual changes
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SYSTEMIC OR EHRAGLANDULAR
MANIFESTATIONS
Shortness of breath
Scarring or fibrosis
Lymphoid infiltrates
Gastrointestinal
Dysphagia
Abnormal esophageal motility
Hepatomegaly
Biliary cirrhosis
Decreased appetite
Weight loss
Genitourinary
Vaginal dryness
Dyspareunia
Hematologic/Circulatory
Vasculifis
Purpura
Lymphoproliferative
Generalized lymphomas
Pseudolymphomas
Macroglobinemia
Renal
Renal fubular acidosis
Nephrogenic diabefes insipidus
Integumentary
Dry skin
Chronic inflammafion of sweaf
glands
Skin ulcération, rashes
Hyperpigmenfafion
Neurologic
Polymyasitis
Peripheral neuropathy
Cranial neuropathy (frigeminal)
Cerebral vasculifis
Inability to concenfrafe
Fafigue/sleep disorders
Depression
Musculoskeletal
Arfhralgias
Nonerosive polyarfhritis
Extra-articular features of rheumafoid
arthrifis in secondary Sjögren's
syndrome
Myalgias

TABLE 2

SAN DIEGO CRITERIA FOR DIAGNOSIS OF SJOGREN'S SYNDROME

The diagnosis of prirriary Sjogren's syndrome is made when two of the following
three cardinal features are present:'
1. Symptoms and objective signs of ocular dryness (Schirmer's test: <8-mm
wetting per 5 minutes, and positive rose bengai staining of cornea to
demonstrate keratoconjunctivitis sicca)
2. Symptoms and objective signs of dry mouth
-Decreased parotid flow rate using Lashley cups or other methods; and
-Abnormal findings from biopsy of minor salivary gland (based on
average of four évaluable lobules)
3. Serologie evidence of systemic autoimmunity
-Elevated rheumatoid factor >1:32O; or
-Elevated antinuclear antibody >1:320; or
-Presence of anti-SS-A(RO) or anti SS-B(LA) antibodies
The diagnosis of secondary Sjogren's syndrome is made when characteristic
signs and symptoms of Sjogren's syndrome (as described above) are present
along with clinical features sufficient to allow for a diagnosis of rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma, or biliary cirrhosis.

for primary care patients presenting
with dry eyes or mouth and parotid
gland enlargement. Nurse practitioners
(NPs) need to differentiate Sjogren's
from other infiltrative processes, autoimmune diseases, and toxic insults
(Table 3). Lack of an absolute laboratory
marker of Sjogren's necessitates a diagnosis based on a combination of factors:
the presence of auto-antibodies, other
assessments, and a cUnical correlation.*
Diagnostic Testing—Selective diagnostic studies are necessary to aid in the
accurate diagnosis of Sjogren's syndrome. According to the San Diego criteria, immunologie tests are not
diagnostic by themselves, but they are
very helpful when interpreted in conjunction with findings from the history
and clinical exam. Once immunologie
tests are performed during the initial
evaluation, they are generally not
repeated often. Primary care providers
should use the following list of laboratory studies to differentiate Sjogren's from
other immune disorders:
Minor salivary gland biopsy remains
the gold standard for definitive diagnosis
of Sjogren's syndrome. A probable diagnosis of the syndrome can be based on
documented decreased salivary function.'

Sjogren's antibodies are frequently
found in patients with Sjogren's syndrome. In 80% of patients with primary
Sjogren's, anti-SSA (formerly SS-A/Ro)
and anti-SSB (formerly SS-B/La) antibodies are present. However, these antibodies are not specific to Sjogren's
syndrome, as they are found in 20% to
60% of patients with SLE and in 3% to
10% of those with RA.'°
Rheumatoid factor (RF) is commonly found in patients with RA, but it
may also be found in patients with other
connective tissues diseases, including
Sjogren's syndrome. A positive RF in a
patient with Sjogren's syndrome does
not necessarily indicate that he or she
has RA as well. An elevated RF (>l:320)
and the presence of anti-SSA or anti-SSB
antibodies provides evidence of systemic autoimmune disease.'
Antinuclear antibody (ANA) is
measured to aid in diagnosing SLE. An
elevated ANA value (>l:320) signals that
practitioners should continue their
investigation for autoimmune involvement. The ANA titer may be positive in
patients with Sjogren's as well; 90% of
those with primary Sjogren's have a
speckled ANA pattern that is typical for
this disorder." However, this test alone
0I.8N0.5

cannot be used to make a definitive diagnosis of SLE (or Sjogren's syndrome, for
that matter) without other accompanying signs and symptoms.'^ Clinical features and exam findings have a higher
degree of importance in assessing disease
activity than does an ANA titer alone.'
Erythrocyte sedimentation rate
(ESR) is helpful in identifying patients
who might have a systemic inflammatory disorder or a connective tissue disorders. An elevated ESR is found in
approximately 70% of patients with
Sjogren's syndrome.'
Immunoglobulins or gamma globulins are elevated in many patients with
Sjogren's syndrome, especially when
there is parenchymal involvement.
Immunoglobulin (Ig)G, IgA, and IgM
antibodies are helpful in monitoring disease activity, particularly in patients
treated with high-dose prednisone and
cyclophosphamide.
Additional Diagnostic Testing—
NPs should perform a urinalysis and
measure blood urea nitrogen and creatinine to determine whether patients
with suspected or documented
Sjogren's syndrome have renal involvement or inflammatory changes.
Chest radiograms may help to assess
for subtle signs of inflammation such
as pneumonitis.
Salivary function tests demonstrate
the amount of saliva production, and,
indirectly, the extent of mucosal dryness. Methods of evaluating salivary status include sialometry, sialography,
sialochemistry, and imaging (ultrasonography, computed tomography,
magnetic resonance imaging [MRI]).'"
Ultrasonography or MRI of the parotid
glands is useful for determining the
presence of glandular cysts, enlargement, and chronic inflammation.
Secretory sialography, an invasive procedure, is not typically used in primary
care management.^
Confirmation of destructive lymphocytic infiltration can be obtained by
biopsy of the minor salivary glands in
the lower lip. Lesions appear as clusters
of lymphocytes that replace and destroy
the secretory acinar tissue. Presence of
this pattern is characteristic of Sjogren's
syndrome.
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DIFFERENTIAL DIAGNOSIS

PAROTID GLAND ENLARGEMENT
Bilateral

XEROPHTHALMIA (DRY EYE)
inflammation

XEROSTOMIA (DRY MOUTH)
Vital infection

Viral infections: mumps, mononucleosis, influenza, EBV, Coxsackie A,
CMV, HIV, HCV
Sarcoidosis
Amyloidosis
Sjögren's syndrome
Metabolic: DM, hyperlipidemia.
chronic pancreatitis, hepatic
cirrhosis
Tuberculosis
Acromegaly
Anorexia or bulimia

Stevens-Johnson syndrome (erythema
multiforme)
Pemphigoid
Conjunctivitis
Blepharitis
Sjögren's syndrome

latrogenic: Irradiation to
head and neck

Unilateral

Burns
Drugs: decongestants, antihistamines.
antihypertensives, acne treatment.
muscle relaxants, tranquilizers.
oral contraceptives

Salivary gland neoplasm
Bacterial infection
Chronic sialadenitis
Obstruction
Lymphoma

EBV = Epstein-Barr virus; CMV =
cytomegalovirus; HIV = human immunodeficiency virus; HCV = hepatitis C
virus; DM = diabetes mellitus.

Schirmer's test, which uses filter
paper to evaluate tear formation by the
lacrimal gland, is easy for NPs to perform in practice. A strip of Whatman
No. 41 filter paper is placed under the
conjunctival sac for 5 minutes, after
which the moistened portion of the
paper is measured. Wetting of less than
5 mm is a strong indicator of diminished
tear secretion (normal tear production is
>10 mm). More reliable diagnostic measures include ocular staining with rose
bengal dye and biomicroscopy (slit lamp
evaluation). Staining of either the conjunctiva or cornea, best seen váth the
biomicroscope, indicates that small
superficial erosions are present—a sign
of primary Sjögren's syndrome.

Treatment
Once NPs make the diagnosis of
Sjögren's syndrome, they should use a
collaborative approach in terms of
1 6 • The Americon Journal for Nurse Proctitioners Moy2004
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Impaired lacrimal or eyelid function
(cranial nerve impairment)
Blepharospasm (uncontrolled blink
reflex)
TfiYlf
f UA ft

Other

Trauma
Hypovitaminosis A
Lid scarring
Anesthetic cornea
Epithelial irregularity
Environmental factors (eg, low
humidity, cigarette smoke exposure, high wind environments)

managing the disease in order to
enhance patient comfort and prevent
complications. An ophthalmologist and
a dentist and/or otorhinolaryngologist
should be consulted for management
issues specific to the patient's symptomatology. A rheumatologist or immunologist may be consulted in patients
with an exacerbation of symptoms or
for re-evaluation. Although Sjögren's is
a chronic, incurable illness, nearly all
patients can lead productive lives with
proper management.
At the same time, NPs should consider the economic burden of the recommended treatment plan. Most of the
items discussed below are available over
the counter (OTC), and are not covered
by insurance. According to the Sjögren's
Syndrome Foundation, a typical patient
may need to spend $625 to $1500 per
year on these products.
Symptom Control—The current
Vol. 8 No. 5

Organic Disease

Autoimmune disease
DM
Hypertension
Dehydration
Sarcoidosis
HIV infection
Sjögren's syndrome
Psychogenic: depression, anorexia,
bulimia, anxiety
Toxins

Medication: antihistamines, antihypertensives; alpha and beta blockers;
parasympatholytic agents; antidepressants, especially tricyclic antidepressants; muscle relaxants;
antispasmodics

treatment approach for patients with
Sjögren's syndrome is conservative, and
is aimed at symptom control. Treatment
can be considered in three phases:
(1) external moisture replacement or
capture (especially important to treat the
oral cavity, eyes, nose, skin, and genital
tract); (2) stimulation of endogenous
secretions, (especially important for the
oral cavity); and (3) treatment of systemic manifestations (ie, pulmonar}' disease, vasculitis, pseudolymphoma)."
Xerophthalmia. The cornerstone of
treatment for xerophthalmia is regular
use of artificial tears, which are used primarily to increase patient comfort. A
variety of artificial aqueous or mucous
tear preparations, as well as an ocular
ointment, can be used to ease the discomfort of ocular dryness (Table 4).^
Artificial tears contain a moisture component and in some products, a preservative. Preservative-free solutions are

^ ^ Q

TREATMENTS FOR XEROPHTHALMIA'

PRESERVED ARTIFICIAL TEARS

NON-PRESERVED TEARS

Absorbotears

AquaSite

Duratears Naturale

BioTears

Hypotears

Cellufresh

Liquifilm

HypoTeors PF

Murocel

Ocular Ointment

Tears Plus

Lacri-Lube

theoretically more prone to bacterial
infection, although many products are
packaged in single-dose vials to reduce
this risk. Preserved artificial tears may
cause burning or irritation, so alternative products must be considered in
these cases. Artificial tears can be used
as frequently as needed, and they are
available ÜTC. Some products (eg,
lubricating ointments) are more viscous
and have longer-lasting effects, but they
also leave a residue and are less preferred by patients than are the aqueous
products." They are generally reserved
for nocturnal use because they can cause
significant blurring of vision.
The following guidelines may be
useful in helping patients to find the
appropriate product(s) to meet their
needs: If artificial tears are not lasting
long enough, use a more viscous tear,
try a tear with a different osmolality use
a tear with a different vehicle, or consider referral to an ophthalmologist for
punctal occlusion (see below). If tears
burn after instillation, choose a tear with
a different preservative or use a non-preserved tear. Patients who dwell in lowhumidity environments should start
using artificial tears as early in the
course of their disease as possible.^
If artificial tears do not provide adequate lubrication and comfort, ophthalmologic surgery can be considered.
Punctal occlusion can provide temporary blockage with collagen plugs or
permanent occlusion with cattery or
laser treatment.^ The purpose of the procedure is to block the punctum, or tear
duct, which carries tears and debris
away from the surface of the eye.
Blocking these drainage ducts prevents
tears from draining away too quickly
and keeps the eyes lubricated.

Last, patients should consider environmental factors that contribute to dry
eyes and cause irritation, such as lowhumidity environments (eg, highly airconditioned spaces, non-humidified
heated areas, airplanes), cigarette smoke,
and windy conditions. Increasing the use
of artificial tears before symptom onset
will help to alleviate discomfort and to
prevent potential corneal abrasion.^ Use
of humidifiers is helpful, as well as wearing wrap-around sunglasses to decrease
tear evaporation when outdoors.
Xerostomia. Dry mouth is a major
contributing factor to dental caries. It is
important to teach patients with
Sjögren's syndrome the importance of
good oral hygiene and the need to avoid
excess sugars. Topical fluorides are warranted to control tooth decay. Patients
can apply fluoride daily, and dental
hygienists can apply it at regular visits to
protect dental enamel. NPs should also
make sure that patients use their toothbrush correctly, and that they floss and
massage their gums to remove debris
between the teeth. Use of toothpastes
targeted at preventing periodontal disease (eg, Retardex, Biotene) can also be
helpful* Some patients obtain relief by
using oral sprays containing mucins and
glycoprotein (eg, Mouthkote, Salivart).
Some patients may need to make
dietary modifications such as ingesting
soft or moist foods only. Others who
retain salivary function may find that
salivary flow stimulation is helpful:
Sugarless gum, hard candy, and mints
can alleviate symptoms and increase
saliva production. Pilocarpine tablets (5
mg 4 times daily) can act as a pharmacologie stimulant to increase salivary flow
for up to 2 hours after ingestion. The
most common side effects of pilocarpine

are sweating and gastrointestinal intolerance, which are controllable by decreasing
the dose. Pilocarpine is contraindicated in
patients with a history of uncontrolled
asthma, peptic ulcer disease, acute iritis,
narrow angle glaucoma, or unstable cardiovascular disease. Response to pilocarpine may take up to 6' weeks."
Cevimeline, an oral muscarinic agonist,
has been shovm to have a longer peak
onset of action than does pilocarpine,
and it is an effective adjunct to treatment. The recommended dosage is 30
mg orally 3 times daily.
Excess water consumption can
remove mucus from the lining of the
buccal mucosa and should be avoided;
patients should be informed that frequent small sips of water are preferable

Classic clinical features
of primary Sjögren's
syndrome include

parotid gland
enlargement,
jcerostomîa, and
xerophthalmia.
for symptom control. NPs should also
educate patients about avoiding medications (prescription and over-thecounter) that cause dry mouth.
Low-grade oral yeast infections are
common in patients vidth Sjögren's syndrome. Topical antifungal troches are
useful in treating this problem.* To
ensure optimal results, patients who
wear dentures should remove them
while the antifungal medication is dissolving in the mouth. Dentures must be treated to remove candidal organisms from the
surface. This can be accomplished by
soaking the dentures overnight in a solution of 1/700 dilution of benzalkonium
chloride and then cleaning them
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carefully with a toothbrush. In severe
cases, oral therapy with a systemic antifungal may be necessary.^
Dry skin. Frequent use of creams or
lotions may be helpful for patients experiencing dry skin. Vaginal dryness is also
a problem for women, and can lead to
dyspareuma. Many different vaginal
lubricants, including topical estrogen,
are available to treat this problem.^
Systemic Manifestations—Whereas
many patients with Sjogren's syndrome
require only local moisturizing therapy
for xerostomia or KCS, others may need
systemic medication for extraglandular
involvement. The armamentarium for
treating systemic manifestations includes
nonsteroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, and immunomodulating drugs (eg, hydroxychloroquine, methotrexate, azathioprine,
cyclophosphamide, gold compounds).
Primary care providers must do a
risk-benefit analysis for each patient
before prescribing such agents.
Disease manifestations of arthralgias,
myalgias, lymphadenopathy, and fatigue
are generally treated with sahcylates,
NSAIDs, and frequently hydroxychloroquine. In fact, the lattermost agent is
one of the most commonly prescribed
medications for patients with Sjogren's
syndrome.^ Although corticosteroids
have no therapeutic role in the glandular
aspects of Sjogren's, they are useful in
patients who have life-threatening complications of the disease,' including vasculitis, skin lesions, pneumonitis,
neuropathy, and nephritis. These
patients are usually very ill, and are hospitalized at this point in their illness.
Tapering of the steroids must be done with
caution; drugs such as hydroxychloroquine, azathioprine, and methotrexate are
useful during the tapering process.^ Many
patients with secondary Sjogren's and
underlying connective tissue disease are
treated with low-dose corticosteroids.
Immunomodulating agents are used to
induce remission in patients with acute
inflammatory processes of rheumatic
conditions and internal organ involvement. By controlling the disease process,
these agents may reduce the need for
corticosteroids and allow for their eventual discontinuation.'"

Prognosis
As with most chronic progressive illnesses, the rate of progression of
Sjogren's syndrome, either primary or
secondary, is highly variable. In general,
the oral and ophthalmologic manifestations of the syndrome do not progress.
Some patients experience only mild
xerostomia and xerophthalmia, which
they are able to manage with topical
agents. Others experience cycles of good
health alternating with episodes of serious illness that are manifested by progression of the disease. This progression
may include blurred vision, constant eye
discomfort, recurrent candidal infection,
swollen parotid glands, hoarseness, dysphagia, and difficulty eating. These
problems, along with debilitating fatigue
and joint pain, contribute to a decreased
quality of life. They may interfere with
simple activities such as watching television or reading, as well as with patients'
ability to work or drive. Furthermore,
patient's with primary Sjogren's syndrome
are at increased risk for lymphoproliferative disorders, including non-Hodgkin's
lymphoma."* Patients with splenomegaly,
bilateral parotid enlargement, and a history of radiation treatment are at especially high risk. Secondary Sjogren's can
progress to damage the vital organs of the
body, complicating the illness and the
course of treatment.

Patient Education
Like any chronic illness, Sjogren's syndrome can have a profound impact on
patients and family members. All may
beneflt from a close relationship with the
primary care provider, as well as a structured support organization. Helping
patients to identify their concerns is
paramount in their ability to cope with
the illness. Integrating relaxation techniques and referral to a mental health
professional may be beneficial for select
patients. As direct caregivers, NPs play a
key role in educating patients with
Sjogren's syndrome. As the disease progresses, they are well suited to counsel
and coach patients through these transitions and to educate patients to maximize the effectiveness and efficiency of
their treatment regimens. By instructing
patients about proper oral hygiene to
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minimize the risk of oral candidiasis and
about proper eye care to prevent dryness, NPs can have a profound impact
on patient adherence and quality of care.

Research
Much research has been performed on
the genetic basis of Sjogren's syndrome
and the nature of the immune component. New data are suggestive of viruses
(eg, retroviruses, EBV, HCV) playing a
role in pathogenesis. Numerous clinical
trials are now recruiting patients to
increase clinicians' understanding of
hormonal underpinnings, diagnostic
techniques, pharmacotherapy, and the
long-term effects of the disease.

Conclusion
Sjogren's syndrome is one of the most
common autoimmune diseases, yet it
can go undiagnosed for 8 to 10 years
because of the nature of the signs and
s^Tuptoms. NPs must be able to recognize the clinical features of the syndrome, to recommend appropriate
studies to diagnosis it, to begin treatment, and to make appropriate referrals.
Easing symptoms and preventing complications are essential to improving
long-term outcomes in the population
affected by Sjogren's syndrome.
Understanding family dynamics and
encouraging family involvement are
vital components to the care of any
patient with a chronic illness. NPs must
think globally in order to educate
patients, families, collaborating clinicians, and researchers to advance the
recognition and treatment of this
autoimmune disease.
Susan DeNisco is an assistant clinical professor and coordinator of the Family Nurse
Practitioner Program at Sacred Heart
University in Fairfield, Connecticut, and
she practices at Southwest Community
Health Center in Bridgeport, Connecticut.
Linda Ferro is a nurse practitioner in the
Section of Endocrinology at Norwalk
Hospital, Norwalk, Connecticut.
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